Clinical Practice Guidelines for the evaluation, treatment and follow up of children who are contacts of patients with tuberculosis in Colombia
Article Sidebar
Main Article Content
Introduction: The available Clinical practice guidelines (CPGs) on latent TB infection (LTBI) are not exclusive to the pediatric population.
Objective: To develop evidence-based recommendations for the evaluation, treatment, and follow-up of children in contact with patients with pulmonary tuberculosis (TB) in Colombia.
Methods: A multidisciplinary development group (composed by clinical and field experts, researchers, and methodologists), including patient representatives and decision-makers formulated 10 questions and prioritized outcomes related to diagnosis (clinical evaluation, chest X-ray, and interferon-gamma release assays-IGRA), treatment (efficacy of regimens in different clinical scenarios), and follow-up (monitoring and strategies to increase adherence) for children with LTBI. We conducted systematic reviews of the literature to identify guidelines, systematic reviews, and primary studies. We assessed the quality and risk of bias of these sources using specific tools. We synthesized the evidence narratively and, in some cases, performed de novo meta-analyses (diagnostics and network meta-analyses). We evaluated the certainty of evidence using the GRADE system. We used the GRADE evidence-to-recommendation framework to formulate the recommendations
Results: We recommends the use of chest X-rays and IGRA tests in children in contact to identify active TB. We recommend short instead of long regimens for children with and without immunosuppression and susceptibility-guided regimens in cases of contact with drug-resistant TB. We recommend monthly clinical follow-up and the implementation of comprehensive approaches to identify barriers to encourage treatment adherence
Conclusions: The group provides context-specific evidence-based recommendations for children with LTBI in Colombia
- latent tuberculosis
- Mycobacterium tuberculosis
- prevention
- isoniazida
- rifapentine
- HIV
Global Tuberculosis P, World Health O. Guidelines on the management of latent tuberculosis infection. Geneva: World Health Organization; 2015. Available from: http://apps.who.int/iris/bitstream/10665/136471/1/9789241548908_eng.pdf?ua=1
Jamison DT. Disease control priorities in developing countries. 2nd ed. New York, Washington, DC: Oxford University Press ; World Bank; 2006.
Schaaf HS, Zumla A, Grange JM. Tuberculosis: a comprehensive clinical reference. Edinburgh: Saunders/Elsevier; 2009.
Small PM, Fujiwara PI. Management of tuberculosis in the United States. N Engl J Med. 2001;345(3):189-200. DOI: 10.1056/NEJM200107193450307
Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016;13(10):e1002152. doi: 10.1371/journal.pmed.1002152.
WHO. Global tuberculosis report 2023. Geneva: World Health Organization; 2023. Geneva; 2023.
Ministerio de Salud y Protección Social. Informe de evento. Tuberculosis, Colombia, 2022. Bogotá, Colombia; 2022.
Ministerio de Salud. Resolución 412 Por la cual se establecen las actividades, procedimientos e intervenciones de demanda inducida y obligatorio cumplimiento y se adoptan las normas técnicas y guías de atención para el desarrollo de las acciones de protección específica y detección temprana y la atención de enfermedades de interés en salud pública. Bogota, Colombia; 2000.
Ministerio de Salud y Protección Social. Guía de Atención de la Tuberculosis Pulmonar y Extrapulmonar. Bogotá: Ministerio de Salud y Protección Social; 2007.
Ministerio de Salud y Protección Social. Resolución 5195 Por la cual se reorganiza el comité asesor de tuberculosis y se dictan otras disposiciones. Bogota; 2010.
Ministerio de Salud y Protección Social. Circular 001 Lineamientos para el manejo programático de los medicamentos de segunda línea para tuberculosis farmacorresistente en Colombia. Bogota, Colombia; 2013.
Ministerio de Salud y Protección Social de Colombia. Plan Estratégico "Hacia el Fin de la Tuberculosis" Colombia 2016-2025. Bogota, Colombia; 2016.
Ministerio de Salud y Protección Social. Resolución 227 por medio de la cual se adoptan los lineamientos técnicos y operativos del programa nacional de prevención y control de la tuberculosis y se dictan otras disposiciones. Bogotá, Colombia; 2020.
WHO. Guidance for national tuberculosis programmes on the management of tuberculosis in children: World Health Organization; 2014.
Beyers N, Gie R, Schaaf H, Van Zyl S, Talent J, Nel E, Donald P. A prospective evaluation of children under the age of 5 years living in the same household as adults with recently diagnosed pulmonary tuberculosis. Int J Tuberc Lung Dis. 1997; 1(1): 38-43.
Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol. 1974; 99(2): 131-8. doi: 10.1093/oxfordjournals.aje.a121593.
Singh M, Mynak ML, Kumar L, Mathew JL, Jindal SK. Prevalence and risk factors for transmission of infection among children in household contact with adults having pulmonary tuberculosis. Arch Dis Child. 2005;90(6):624-8. doi: 10.1136/adc.2003.044255.
Topley JM, Maher D, Mbewe LN. Transmission of tuberculosis to contacts of sputum positive adults in Malawi. Arch Dis Child. 1996;74(2):140-3. doi: 10.1136/adc.74.2.140.
WHO. Implementing the WHO Stop TB Strategy: a handbook for national TB control programmes: World Health Organization; 2008.
Rieder H. Contacts of tuberculosis patients in high-incidence countries. Int J Tuberc Lung Dis. 2003; 7(12 suppl 3): S333-S6.
Zachariah R, Spielmann M, Harries A, Gomani P, Graham S, Bakali E, Humblet P. Passive versus active tuberculosis case finding and isoniazid preventive therapy among household contacts in a rural district of Malawi. Int J Tuberc Lung Dis. 2003;7(11):1033-9.
Marks SM, Taylor Z, Qualls NL, Shrestha-Kuwahara RJ, Wilce MA, Nguyen CH. Outcomes of Contact Investigations of Infectious Tuberculosis Patients. Am J Respir Crit Care Med. 2000;162(6):2033-8. doi: 10.1164/ajrccm.162.6.2004022
Reichler MR, Etkind S, Taylor Z, Castro KG. Tuberculosis contact investigations. Int J Tuberc Lung Dis. 2003;7(12 Suppl 3):S325-7.
Salgame P, Geadas C, Collins L, Jones-López E, Ellner JJ. Latent tuberculosis infection-revisiting and revising concepts. Tuberculosis. 2015;95(4):373-84. doi: 10.1016/j.tube.2015.04.003.
WHO. Global Tuberculosis Report 2023. Geneva; 2023. Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023
Chen Y, Yang K, Marusic A, Qaseem A, Meerpohl JJ, Flottorp S, et al. A reporting tool for practice guidelines in health care: the RIGHT statement. Ann Intern Med. 2017;166(2):128-32. doi: 10.7326/M16-1565.
Brouwers MC, Kerkvlieter K, Spithoff K. The AGREE reporting checklist: a tool to improve reporting of clinical practice guidelines. BMJ. 2016; 352: i1152.
Yao X, Ma J, Wang Q, Kanters D, Ali MU, Florez ID. A Comparison of AGREE and RIGHT: which Clinical Practice Guideline Reporting Checklist Should Be Followed by Guideline Developers? J Gen Intern Med. 2020;35(3):894-8. doi: 10.1007/s11606-019-05508-3.
Ministerio de Salud y Proteccion Social. Guía Metodológica para la elaboración de Guías de Práctica Clínica con Evaluación Económica en el Sistema General de Seguridad Social en Salud Colombiano. Bogotá, Colombia; 2014. Available from: https://www.minsalud.gov.co/salud/Documents/Gu%C3%ADa%20Metodol%C3%B3gica%20para%20la%20elaboraci%C3%B3n%20de%20gu%C3%ADas.pdf
Schünemann HJ, Al-Ansary LA, Forland F, Kersten S, Komulainen J, Kopp IB, et al. Guidelines International Network: Principles for Disclosure of Interests and Management of Conflicts in Guidelines. Ann Intern Med. 2015;163(7):548-53. doi: 10.7326/M14-1885.
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383-94. doi: 10.1016/j.jclinepi.2010.04.026.
Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011;64(4):395-400. doi: 10.1016/j.jclinepi.2010.09.012.
Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010; 182(18): E839-42. doi: 10.1503/cmaj.090449.
Brouwers MC, Spithoff K, Lavis J, Kho ME, Makarski J, Florez ID. What to do with all the AGREEs? The AGREE portfolio of tools to support the guideline enterprise. J Clin Epidemiol. 2020;125:191-7. doi: 10.1016/j.jclinepi.2020.05.025.
Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. Bmj. 2017;358:j4008. doi: 10.1136/bmj.j4008.
Sterne JA, Hernán MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355: i4919.
doi: 10.1136/bmj.i4919
Sterne JA, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898. doi: 10.1136/bmj.l4898.
Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ. 2016;353:i2089. doi: 10.1136/bmj.i2089.
Alonso-Coello P, Schünemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ. 2016;353:i2016. doi: 10.1136/bmj.i2016.
Plana MN, Arevalo-Rodriguez I, Fernández-García S, Soto J, Fabregate M, Pérez T, et al. Meta-DiSc 2.0: a web application for meta-analysis of diagnostic test accuracy data. BMC Med Res Methodol. 2022;22(1):306. doi: 10.1186/s12874-022-01788-2.
Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10(10):Ed000142. doi: 10.1002/14651858.ED000142.
Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence-indirectness. J Clin Epidemiol. 2011;64(12):1303-10. doi: 10.1016/j.jclinepi.2011.04.014.
Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence--inconsistency. J Clin Epidemiol. 2011;64(12):1294-302. doi: 10.1016/j.jclinepi.2011.03.017.
Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol. 2011;64(12):1283-93. doi: 10.1016/j.jclinepi.2011.01.012.
Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence--publication bias. J Clin Epidemiol. 2011;64(12):1277-82. doi: 10.1016/j.jclinepi.2011.01.011.
Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). J Clin Epidemiol. 2011;64(4):407-15. doi: 10.1016/j.jclinepi.2010.07.017.
Schünemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeflang M, Murad MH, et al. GRADE guidelines: 21 part 1. Study design, risk of bias, and indirectness in rating the certainty across a body of evidence for test accuracy. J Clin Epidemiol. 2020;122:129-41. doi: 10.1016/j.jclinepi.2019.12.020.
Schünemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeflang M, Murad MH, et al. GRADE guidelines: 21 part 2. Test accuracy: inconsistency, imprecision, publication bias, and other domains for rating the certainty of evidence and presenting it in evidence profiles and summary of findings tables. J Clin Epidemiol. 2020;122:142-52. doi: 10.1016/j.jclinepi.2019.12.021.
Brignardello-Petersen R, Bonner A, Alexander PE, Siemieniuk RA, Furukawa TA, Rochwerg B, et al. Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. J Clin Epidemiol. 2018;93:36-44. doi: 10.1016/j.jclinepi.2017.10.005.
Brignardello-Petersen R, Guyatt GH, Mustafa RA, Chu DK, Hultcrantz M, Schünemann HJ, Tomlinson G. GRADE guidelines 33: Addressing imprecision in a network meta-analysis. J Clin Epidemiol. 2021;139:49-56. doi: 10.1016/j.jclinepi.2021.07.011.
Brignardello-Petersen R, Mustafa RA, Siemieniuk RAC, Murad MH, Agoritsas T, Izcovich A, et al. GRADE approach to rate the certainty from a network meta-analysis: addressing incoherence. J Clin Epidemiol. 2019;108:77-85. doi: 10.1016/j.jclinepi.2018.11.025.
Brignardello-Petersen R, Tomlinson G, Florez I, Rind DM, Chu D, Morgan R, et al. Grading of recommendations assessment, development, and evaluation concept article 5: addressing intransitivity in a network meta-analysis. J Clin Epidemiol. 2023;160:151-9. doi: 10.1016/j.jclinepi.2023.06.010.
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-6. doi: 10.1136/bmj.39489.470347.AD.
Zhang Y, Coello PA, Brozek J, Wiercioch W, Etxeandia-Ikobaltzeta I, Akl EA, et al. Using patient values and preferences to inform the importance of health outcomes in practice guideline development following the GRADE approach. Health Qual Life Outcomes. 2017; 15(1): 52. doi: 10.1186/s12955-017-0621-0.
Navarro CE, Benjumea-Bedoya D, Estupinan-Bohorquez AF, Florez ID. Cost-effectiveness analysis comparing QuantiFERON test and tuberculin skin test for the diagnosis of latent tuberculosis infection in immunocompetent children under 15 years of age in Colombia. BMJ Open. 2025; 15(3):e087333. doi: 10.1136/bmjopen-2024-087333.
Sanabria AJ, Alonso-Coello P, McFarlane E, Niño de Guzman E, Roqué M, Martínez García L. The UpPriority tool supported prioritization processes for updating clinical guideline questions. J Clin Epidemiol. 2021;139:149-59. doi: 10.1016/j.jclinepi.2021.07.022.
Clemente MG, Dore E, Abis L, Molicotti P, Zanetti S, Olmeo P, Antonucci R. Pediatric tuberculosis in northern Sardinia. Mediterranean Journal of Hematology and Infectious Diseases. 2017;9(1): e2017027. doi: 10.4084/MJHID.2017.027.
Kruk A, Gie RP, Schaaf HS, Marais BJ. Symptom-based screening of child tuberculosis contacts: improved feasibility in resource-limited settings. Pediatrics. 2008;121(6):e1646-e52. doi: 10.1542/peds.2007-3138.
Rossoni AM, Lovero KL, Tahan TT, Netto AR, Rossoni MD, Almeida IN, et al. Evaluation of pulmonary tuberculosis diagnostic tests in children and adolescents at a pediatric reference center. Pulmonology. 2022;28(2):83-9. doi: 10.1016/j.pulmoe.2020.01.001.
Triasih R, Robertson CF, Duke T, Graham SM. A prospective evaluation of the symptom-based screening approach to the management of children who are contacts of tuberculosis cases. Clin Infect Dis. 2015;60(1):12-8. doi: 10.1093/cid/ciu748.
Benjumea-Bedoya D. Efectividad del tratamiento para infección latente por tuberculosis en niños menores de cinco años convivientes de pacientes con tuberculosis pulmonar de Medellín. Bello e Itagüí. Tesis Doctorado. Doctorado en Salud Pública, Universidad de Antioquia: Medellin; 2018.
Benjumea-Bedoya D, Villegas Arbeláez E, Martínez-Peñaloza D, Beltrán-Arroyave CP, Restrepo Gouzy AV, Marín D, et al. Implementation of an integrated care strategy for child contacts of tuberculosis patients: a quasi-experimental study protocol. BMC pediatrics. 2023;23(1):28. doi: 10.1186/s12887-022-03798-x.
Choi J-W, Kim M-S, Kim J-H. Comparison of results between tuberculin skin test and QuantiFERON(r)-TB in-tube assay for diagnosis of latent tuberculosis infection in children and adolescents. Korean Journal of Pediatric Infectious Diseases. 2013;20(1):17-27.
Debulpaep S, Corbière V, Levy J, Schelstraete P, Vanden Driessche K, Mascart F, Mouchet F. Contribution of QuantiFERON-TB Gold-in-Tube to the Diagnosis of Mycobacterium tuberculosis Infection in Young Children in a Low TB Prevalence Country. Front Pediatr. 2019;7:291. doi: 10.3389/fped.2019.00291
Benachinmardi K, Sampath S, Rao M. Evaluation of a new interferon gamma release assay, in comparison to tuberculin skin tests and quantiferon tuberculosis goldplus for the detection of latent tuberculosis infection in children from a high tuberculosis burden setting. The International Journal of Mycobacteriology. 2021;10(2):142-8. doi: 10.4103/ijmy.ijmy_44_21.
Velasco-Arnaiz E, Soriano-Arandes A, Latorre I, Altet N, Domínguez J, Fortuny C, et al. Performance of tuberculin skin tests and interferon-? release assays in children younger than 5 years. The Pediatric Infectious Disease Journal. 2018;37(12):1235-41. doi: 10.1097/INF.0000000000002015.
Song S-E, Yang J, Lee KS, Kim H, Kim YM, Kim S, et al. Comparison of the tuberculin skin test and interferon gamma release assay for the screening of tuberculosis in adolescents in close contact with tuberculosis TB patients. PLOS one. 2014;9(7):e100267. doi: 10.1371/journal.pone.0100267.
Kasambira TS, Shah M, Adrian PV, Holshouser M, Madhi SA, Chaisson RE, et al. QuantiFERON-TB Gold In-Tube for the detection of Mycobacterium tuberculosis infection in children with household tuberculosis contact. Int J Tuberc Lung Dis. 2011;15(5):628-34. doi: 10.5588/ijtld.10.0555.
Setiawati L, Endaryanto A, Kusumadewi A, Lestari P. Effect of BCG vaccination and non tuberculous Mycobacterium infection on interferon gamma specific assay and a tuberculin skin test among children with a tuberculosis contact in Surabaya, Indonesia. Southeast Asian J Trop Med Public Health. 2011;42(6):1460-8.
Diel R, Loddenkemper R, Niemann S, Meywald-Walter K, Nienhaus A. Negative and positive predictive value of a whole-blood interferon-? release assay for developing active tuberculosis: an update. Am J Respir Crit Care Med. 2011;183(1):88-95. doi: 10.1164/rccm.201006-0974OC.
Mahomed H, Hawkridge T, Verver S, Abrahams D, Geiter L, Hatherill M, et al. The tuberculin skin test versus QuantiFERON TB Gold(r) in predicting tuberculosis disease in an adolescent cohort study in South Africa. PloS one. 2011;6(3):e17984. doi: 10.1371/journal.pone.0017984.
Noorbakhsh S, Mousavi J, Barati M, Shamshiri A, Shekarabi M, Tabatabaei A, Soleimani G. Evaluation of an interferon-gamma release assay in young contacts of active tuberculosis cases. East Mediterr Health J. 2011; 17 (9): 714-718.
Magdorf K, Arizzi-Rusche A, Geiter l, O'brien R, Wahn U. Compliance und toleranz neuer antituberkulotischer kurzzeit-chemopraventionsregime im kindesalter-eine pilotstudie. Pneumologie. 1994; 48(10): 761-4.
Spyridis NP, Spyridis PG, Gelesme A, Sypsa V, Valianatou M, Metsou F, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3-and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clinical Infectious Diseases. 2007;45(6):715-22. Doi: 10.1086/520983
Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, et al. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA pediatrics. 2015;169(3):247-55. doi: 10.1001/jamapediatrics.2014.3158
Comstock GW, Ferebee SH, Hammes LM. A controlled trial of community-wide isoniazid prophylaxis in Alaska. American Review of Respiratory Disease. 1967;95(6):935-43. doi: 10.1164/arrd.1967.95.6.935.
Diallo T, Adjobimey M, Ruslami R, Trajman A, Sow O, Obeng Baah J, et al. Safety and side effects of rifampin versus isoniazid in children. N Engl J Med. 2018;379(5):454-63. doi: 10.1056/NEJMoa1714284
Egsmose T, Ang´Awa J, Poti S. The use of isoniazid among household contacts of open cases of pulmonary tuberculosis. Bulletin of the World Health Organization. 1965;33(3):419.
Biraro IA, Egesa M, Kimuda S, Smith SG, Toulza F, Levin J, et al. Effect of isoniazid preventive therapy on immune responses to mycobacterium tuberculosis: an open label randomised, controlled, exploratory study. BMC infect dis. 2015;15:1-12. doi: 10.1186/s12879-015-1201-8.
Yanes-Lane M, Ortiz-Brizuela E, Campbell JR, Benedetti A, Churchyard G, Oxlade O, et al. Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis. PLoS Medicine. 2021;18(9):e1003738. doi: 10.1371/journal.pmed.1003738.
Gray DM, Young T, Cotton M, Zar H. Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children. Cochrane Database Syst Rev. 2009; (1): CD006418. doi: 10.1002/14651858.CD006418.pub2.
Zunza M, Gray DM, Young T, Cotton M, Zar HJ. Isoniazid for preventing tuberculosis in HIV-infected children. Cochrane Database Syst Rev. 2017; 8(8): CD006418. doi: 10.1002/14651858.CD006418.pub3.
Gray D, Workman L, Lombard C, Jennings T, Innes S, Grobbelaar C, et al. Isoniazid preventive therapy in HIV-infected children on antiretroviral therapy: a pilot study. Int J Tuberc Lung Dis. 2014; 18(3): 322-7. doi: 10.5588/ijtld.13.0354.
Madhi SA, Nachman S, Violari A, Kim S, Cotton MF, Bobat R, et al. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. N Engl J Med. 2011; 365(1) :21-31. doi: 10.1056/NEJMoa1011214.
Zar HJ, Cotton MF, Strauss S, Karpakis J, Hussey G, Schaaf HS, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ. 2007;334(7585):136. doi: 10.1136/bmj.39000.486400.55.
Churchyard G, Cárdenas V, Chihota V, Mngadi K, Sebe M, Brumskine W, et al. Annual tuberculosis preventive therapy for persons with HIV infection: a randomized trial. Ann Intern Med.. 2021;174(10):1367-76. doi: 10.7326/M20-7577.
Chen Y-M, Liao T-L, Chen H-H, Chen D-Y. Three months of once-weekly isoniazid plus rifapentine (3HP) in treating latent tuberculosis infection is feasible in patients with rheumatoid arthritis. Ann Rheum Dis. 2018;77(11):1688-9.
Huang H-L, Huang W-C, Lin K-D, Liu S-S, Lee M-R, Cheng M-H, et al. Completion rate and safety of programmatic screening and treatment for latent tuberculosis infection in elderly patients with poorly controlled diabetic mellitus: a prospective multicenter study. Clin Infect Dis. 2021;73(6):e1252-e60. doi: 10.1093/cid/ciab209.
Lin S-Y, Feng J-Y, Lee C-Y, Lin Y-C, Chou Y-H, Lin K-Y, et al. Completion and adverse drug events of latent tuberculosis infection treatment in patients receiving dialysis: predictors and impacts of different regimens in a prospective cohort study. Antimicrobial Agents and Chemotherapy. 2021;65(3): e02184-20. doi: 10.1128/AAC.02184-20.
Adler-Shohet FC, Low J, Carson M, Girma H, Singh J. Management of Latent Tuberculosis Infection in Child Contacts of Multidrug-Resistant Tuberculosis. Pediatr Infect Dis J. 2014;33(6):664-6. doi: 10.1097/INF.0000000000000260.
Malik AA, Fuad J, Siddiqui S, Amanullah F, Jaswal M, Barry Z, et al. Tuberculosis preventive therapy for individuals exposed to drug-resistant tuberculosis: feasibility and safety of a community-based delivery of fluoroquinolone-containing preventive regimen. Clin Infect Dis. 2020;70(9):1958-65. doi: 10.1093/cid/ciz502.
Malik AA, Gandhi NR, Lash TL, Cranmer LM, Omer SB, Ahmed JF, et al. Effectiveness of Preventive Therapy for Persons Exposed at Home to Drug-Resistant Tuberculosis, Karachi, Pakistan. Emerg Infect Dis. 2021;27(3):805-12. doi: 10.3201/eid2703.203916
Feja K, McNelley E, Tran CS, Burzynski J, Saiman L. Management of Pediatric Multidrug-Resistant Tuberculosis and Latent Tuberculosis Infections in New York City From 1995 to 2003. Pediatr Infect Dis J. 2008;27(10):907-12. doi: 10.1097/INF.0b013e3181783aca
Bamrah S, Brostrom R, Dorina F, Setik L, Song R, Kawamura LM, et al. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012. Int J Tuberc Lung Dis. 2014;18(8):912-8. doi: 10.5588/ijtld.13.0028.
Garcia-Prats AJ, Zimri K, Mramba Z, Schaaf HS, Hesseling AC. Children exposed to multidrug-resistant tuberculosis at a home-based day care centre: a contact investigation. Int J Tuberc Lung Dis. 2014;18(11):1292-8. doi: 10.5588/ijtld.13.0872.
Schaaf HS, Gie RP, Kennedy M, Beyers N, Hesseling PB, Donald PR. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics. 2002;109(5):765-71. doi: 10.1542/peds.109.5.765.
The Australian New Zealand Clinical Trials Registry. The V-QUIN MDR TRIAL: A randomized controlled trial of six months of daily levofloxacin for the prevention of tuberculosis among household contacts of patients with multi-drug resistant tuberculosis. Registry: ACTRN12616000215426. Camperdown: The Australian New Zealand Clinical Trials Registry; 2016. https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369817.
World Health Organization. WHO consolidated guidelines on tuberculosis. Module 1: prevention - tuberculosis preventive treatment, second edition. Geneva: World Health Organization; 2024.
Martinez L, Cords O, Horsburgh CR, Andrews JR, Acuna-Villaorduna C, Desai Ahuja S, et al. The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. Lancet. 2020;395(10228):973-84. doi: 10.1016/S0140-6736(20)30166-5.
100. Benjumea-Bedoya D, Marín DM, Robledo J, Barrera LF, López L, del Corral H, et al. Risk of infection and disease progression in children exposed to tuberculosis at home, Colombia. Colomb Med (Cali). 2019; 50: 261-74. doi: 10.25100/cm.v50i4.4185.
Cruz AT, Starke JR. Window Period Prophylaxis for Children Exposed to Tuberculosis, Houston, Texas, USA, 2007-2017. Emerg Infect Dis. 2019;25(3):523-8. doi: 10.3201/eid2503.181596.
Aminzadeh Z, Asl RT. A six months follow-up on children less than 6 years old in contact with smear positive tuberculosis patients, varamin city, tehran, iran. Int J Prev Med. 2011;2(2):79-81.
Bekker A, Slogrove AL, Schaaf HS, Du Preez K, Hesseling AC. Determinants of tuberculosis treatment completion among newborns in a high-burden setting. Int J Tuberc Lung Dis. 2014;18(3):335-40. doi: 10.5588/ijtld.13.0506.
Triasih R, Robertson CF, Duke T, Graham SM. A Prospective evaluation of the symptom-based screening approach to the management of children who are contacts of tuberculosis cases. Clin Infect Dis. 2014;60(1):12-8. doi: 10.1093/cid/ciu748.
Garie KT, Yassin MA, Cuevas LE. Lack of adherence to isoniazid chemoprophylaxis in children in contact with adults with tuberculosis in Southern Ethiopia. PLoS One. 2011;6(11):e26452. doi: 10.1371/journal.pone.0026452.
Gomes VF, Wejse C, Oliveira I, Andersen A, Vieira FJ, Carlos LJ, et al. Adherence to isoniazid preventive therapy in children exposed to tuberculosis: a prospective study from Guinea-Bissau. Int J Tuberc Lung Dis. 2011;15(12):1637-43. doi: 10.5588/ijtld.10.0558.
Perry A, Angoulvant F, Chadelat K, De Lauzanne A, Houdouin V, Kheniche A, et al. Contage tuberculeux néonatal en maternité : dépistage et évolution d'une cohorte de nourrissons exposés. Archives de Pédiatrie. 2012;19(4):396-403. doi: 10.1016/j.arcped.2012.01.017.
Bonnet M, Kyakwera C, Kyomugasho N, Atwine D, Mugabe F, Nansumba M, et al. Prospective cohort study of the feasibility and yield of household child tuberculosis contact screening in Uganda. Int J Tuberc Lung Dis. 2017;21(8):862-8. doi: 10.5588/ijtld.16.0889.
Adams LV, Talbot EA, Odato K, Blunt H, Steingart KR. Interventions to improve delivery of isoniazid preventive therapy: an overview of systematic reviews. BMC infect dis. 2014;14:281. doi: 10.1186/1471-2334-14-281.
Liu Q, Abba K, Alejandria MM, Sinclair D, Balanag VM, Lansang MAD. Reminder systems to improve patient adherence to tuberculosis clinic appointments for diagnosis and treatment. Cochrane Database of Systematic Reviews. 2014; 2014(11): CD006594. doi: 10.1002/14651858.CD006594.pub3.
M´imunya JM, Kredo T, Volmink J. Patient education and counselling for promoting adherence to treatment for tuberculosis. Cochrane database of systematic reviews. 2012; 2012(5): CD006591. doi: 10.1002/14651858.CD006591.pub2.
Stuurman AL, Vonk Noordegraaf-Schouten M, van Kessel F, Oordt-Speets AM, Sandgren A, van der Werf MJ. Interventions for improving adherence to treatment for latent tuberculosis infection: a systematic review. BMC infect dis. 2016;16: 257. doi: 10.1186/s12879-016-1549-4.
Wingfield T, Tovar MA, Huff D, Boccia D, Montoya R, Ramos E, et al. A randomized controlled study of socioeconomic support to enhance tuberculosis prevention and treatment, Peru. Bull World Health Organ. 2017;95(4):270-280. doi: 10.2471/BLT.16.170167.
Surey J, Stagg HR, Yates TA, Lipman M, White PJ, Charlett A, et al. An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study. BMC infect dis. 2021; 21(1): 90. doi: 10.1186/s12879-021-05766-9.
Semitala FC, Kadota JL, Musinguzi A, Nabunje J, Welishe F, Nakitende A, et al. Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial. PLoS med. 2021;18(12):e1003875. doi: 10.1371/journal.pmed.1003875.
Belknap R, Holland D, Feng P-J, Millet J-P, Caylà JA, Martinson NA, et al. Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial. Ann Intern Med. 2017;167(10):689-97. doi: 10.7326/M17-1150.
Johnston JC, van der Kop ML, Smillie K, Ogilvie G, Marra F, Sadatsafavi M, et al. The effect of text messaging on latent tuberculosis treatment adherence: a randomised controlled trial. Eur Respir J. 2018;51(2): 1701488. doi: 10.1183/13993003.01488-2017.
Downloads
Funding data
-
Ministerio de Ciencia, Tecnología e Innovación,Departamento Administrativo de Ciencia, Tecnología e Innovación (COLCIENCIAS)
Grant numbers Convocatoria 842-2019 para presentar programas de investigación en temáticas priorizadas en ciencias del Programa Nacional de Ciencia, Tecnología e Innovación en Salud, contrato del programa 902-2019, con el código de registro del proyecto 68743
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The copy rights of the articles published in Colombia Médica belong to the Universidad del Valle. The contents of the articles that appear in the Journal are exclusively the responsibility of the authors and do not necessarily reflect the opinions of the Editorial Committee of the Journal. It is allowed to reproduce the material published in Colombia Médica without prior authorization for non-commercial use